Zymeworks/$ZYME
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zymeworks
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Ticker
$ZYME
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
299
ISIN
US98985Y1082
Website
Zymeworks Metrics
BasicAdvanced
$880M
-
-$1.50
1.17
-
Price and volume
Market cap
$880M
Beta
1.17
52-week high
$17.11
52-week low
$8.21
Average daily volume
438K
Financial strength
Current ratio
4.707
Quick ratio
4.453
Long term debt to equity
4.678
Total debt to equity
5.682
Profitability
EBITDA (TTM)
-99.293
Gross margin (TTM)
-49.38%
Net profit margin (TTM)
-121.73%
Operating margin (TTM)
-116.52%
Effective tax rate (TTM)
-6.07%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-13.89%
Return on equity (TTM)
-29.80%
Valuation
Price to revenue (TTM)
10.223
Price to book
2.7
Price to tangible book (TTM)
2.84
Price to free cash flow (TTM)
-12.157
Free cash flow yield (TTM)
-8.23%
Free cash flow per share (TTM)
-103.89%
Growth
Revenue change (TTM)
85.05%
Earnings per share change (TTM)
-14.96%
3-year revenue growth (CAGR)
49.49%
3-year earnings per share growth (CAGR)
-32.86%
What the Analysts think about Zymeworks
Analyst ratings (Buy, Hold, Sell) for Zymeworks stock.
Bulls say / Bears say
Zymeworks' lead candidate, zanidatamab, has been submitted for a Biologics License Application (BLA) to the FDA for accelerated approval in treating HER2-positive biliary tract cancer, potentially leading to significant revenue upon approval. (Zymeworks Inc.)
The company maintains a strong cash position of $456.3 million as of December 31, 2023, expected to fund operations into the second half of 2027, providing financial stability for ongoing research and development. (Nasdaq)
Strategic collaborations with Jazz Pharmaceuticals and BeiGene for the development and commercialization of zanidatamab enhance Zymeworks' market reach and potential revenue streams. (Zymeworks Inc.)
Zymeworks reported a net loss of $118.7 million in 2023, a significant decline from a net income of $124.3 million in 2022, primarily due to an 82% decrease in total revenue. (GuruFocus)
The company's revenue per employee has declined to $65,130, placing it lower compared to peers in the healthcare sector, indicating potential operational inefficiencies. (CSIMarket)
Zymeworks' reliance on future milestone payments from partners introduces uncertainty in funding ongoing operations and increasing R&D expenses, especially with the absence of large one-time payments like the $375 million received from Jazz Pharmaceuticals in 2022. (Panabee)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
Zymeworks Financial Performance
Revenues and expenses
Zymeworks Earnings Performance
Company profitability
Zymeworks News
AllArticlesVideos
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
GlobeNewsWire·3 weeks ago
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
GlobeNewsWire·4 weeks ago
Zymeworks Announces Participation in Upcoming Investor Conferences
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zymeworks stock?
Zymeworks (ZYME) has a market cap of $880M as of June 20, 2025.
What is the P/E ratio for Zymeworks stock?
The price to earnings (P/E) ratio for Zymeworks (ZYME) stock is 0 as of June 20, 2025.
Does Zymeworks stock pay dividends?
No, Zymeworks (ZYME) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Zymeworks dividend payment date?
Zymeworks (ZYME) stock does not pay dividends to its shareholders.
What is the beta indicator for Zymeworks?
Zymeworks (ZYME) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.